Survey
Quarterly Survey: Demodex Blepharitis and TARS Xdemvy January 2026
Ticker(s): TARSAll 20 experts are optometrists or ophthalmologists.
Approximately how many patients with Demodex blepharitis do you currently manage per month?
Are you familiar with Xdemvy (lotilaner ophthalmic solution) and the data to date?
- Yes
- No
How would you best describe your practice?
- Academic
- Community
- Commercial
- Private
- Other please specify
Of your Demodex blepharitis patients, about what percentage (%) are symptomatic enough that you would consider prescribing a prescription therapy?
What percentage (%) of your Demodex blepharitis patient would you consider eligible for Xdemvy (lotilaner ophthalmic solution)?
What is your view on Xdemvy (lotilaner ophthalmic solution) as a treatment option for Demodex blepharitis? Please be specific.
How do you currently manage patients with Demodex blepharitis in your practice? Please allocate by percentage of patients (i.e., the primary approach used for most patients). Must total 100%.
- Eyelid hygiene / warm compresses
- Tea tree oil–based products
- Topical antibiotics
- Oral medications
- Prescription anti-Demodex therapy (e.g., Xdemvy)
- Observation / no active treatment
- Other (please specify)
How do you expect to manage patients with Demodex blepharitis in your practice 12 months from now? Please allocate by percentage of patients (i.e., the primary approach used for most patients). Must total 100%.
- Eyelid hygiene / warm compresses
- Tea tree oil–based products
- Topical antibiotics
- Oral medications
- Prescription anti-Demodex therapy (e.g., Xdemvy)
- Observation / no active treatment
- Other (please specify)
How many of your patients with Demodex blepharitis do you expect to be Xdemvy (lotilaner ophthalmic solution) at the following time points?
- By March 31, 2026:
- In 1 year:
- In 3 years:
- In 5 years:
How will cost specifically impact access to Xdemvy (lotilaner ophthalmic solution) for patients with Demodex blepharitis?
- No impact
- Minor impact
- Moderate impact
- Significant impact
- I am not sure
How does Xdemvy (lotilaner ophthalmic solution) compare to other treatments in treating patients with Demodex blepharitis? Please be specific.
What line of treatment would you consider Xdemvy (lotilaner ophthalmic solution) for patients with Demodex blepharitis?
Do you think that Xdemvy (lotilaner ophthalmic solution) will grow the market for Demodex blepharitis treatments?
- Yes
- No
Why or why not? Please elaborate on your response above.
On a scale 1-10 (where 1 is low and 10 is high) how excited are you for Xdemvy (lotilaner ophthalmic solution) in treating Demodex blepharitis?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
